7,770
0.00%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Daewon Pharmaceutical Co
Its shares trade on KRX under the ticker 003220.KS. It has been listed since 15 December 1999. In the fiscal year to 31 December 2025, it reported revenue of ₩605.43bn and a net loss of ₩1.38bn. At that date it held total assets of ₩613.65bn and shareholders' equity of ₩265.92bn.
Daewon Pharmaceutical Co., Ltd. engages in the production and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The firm also produces multivitamins and health foods. The firm distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Dec 1999
- Website
- daewonpharm.com/main/index.jsp ↗
Leadership
Pay as last reported
- Mr. In BaekPresident, Co-Chief Executive Officer, Director
- Mr. Tae Hong ChoiCo-President
- Mr. Byeong Ho YoonCo-President
- Mr. Seung Yeol BaekCo-Chief Executive Officer, Vice Chairman, Director, since 2018
- Mr. Yeon Seop KimManaging Director
- Mr. Hui Byeong ByunManaging Director, since 2022
- Mr. Bong Cheol ChoManaging Director
- Mr. Ju Yil KimManaging Director
- Mr. Gyeong Jun LeeManaging Director
- Ms. So Ra LeeManaging Director
- Mr. Se Yil SonManaging Director
- Mr. Han Yil YimManaging Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Daewon Pharmaceutical produces antipyretics and analgesics for domestic and international markets.
- The company distributes cardiovascular and metabolic drugs across Southeast Asia and the Middle East.
- Daewon offers a wide range of pharmaceutical products including respiratory and gastrointestinal drugs.
Weaknesses
- Daewon Pharmaceutical's product range lacks focus on emerging markets like Africa.
- The company has limited presence in the European pharmaceutical sector.
- Daewon's distribution network does not cover North American markets effectively.
Opportunities
- Expanding into Vietnam and Myanmar offers growth in Southeast Asian pharmaceutical markets.
- Increasing demand for metabolic drugs in the Middle East presents new opportunities.
- Growing health food market in Southeast Asia aligns with Daewon's multivitamin production.
Threats
- Competition from established pharmaceutical firms in the Middle East threatens market share.
- Regulatory changes in Southeast Asia could impact Daewon's distribution channels.
- Economic instability in Myanmar may affect pharmaceutical sales in that region.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.